In regions where accessing healthcare facilities for routine blood tests is financially and logistically challenging, HIV patients now have a more convenient alternative. Researchers at Tufts University have developed an innovative paper-based device that absorbs and stores blood samples for remote analysis. This advancement addresses the limitations of existing technologies, which often fail to control the volume of blood collected, leading to potential inaccuracies in monitoring the progression of HIV and adherence to treatment regimens. The new device, known as a plasma spot card, has demonstrated superior accuracy compared to industry standards, providing better insights into patient health and drug resistance.

The challenge of collecting consistent blood volumes has long been a concern for healthcare providers working with HIV patients. To address this issue, Charlie Mace, an associate professor at Tufts University's Department of Chemistry, along with his team, engineered a paper device featuring wax-printed patterns. These patterns create precise channels and collection spots, ensuring that each sample contains the same volume of blood. In a clinical pilot involving 75 South African patients, the plasma spot card outperformed the Roche plasma spot card, achieving higher accuracy in measuring HIV infection levels (90.5% vs. 82.7%) and detecting drug-resistant viral mutations (63% vs. 42%).

Mace’s innovation not only enhances diagnostic precision but also aligns seamlessly with current medical workflows. By maintaining simplicity in design and operation, the device is more likely to be adopted by healthcare professionals. The research was published in the Proceedings of the National Academy of Sciences on February 18. Collaboration with the National Institute for Communicable Diseases in Johannesburg played a crucial role in validating the device’s effectiveness in real-world conditions. Scientists from NICD provided valuable insights, enabling Tufts researchers to conduct comparative studies in an active clinical setting.

Mace and his team are now exploring opportunities to integrate this technology into regular practice through partnerships with laboratories and researchers globally. They continue to refine the device, aiming to further enhance its accuracy and capabilities while pursuing commercialization. The focus remains on creating accessible and affordable solutions, addressing critical needs in healthcare. Through these efforts, the plasma spot card promises to revolutionize how HIV is monitored and managed, particularly in underserved areas.